JP2012512871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512871A5 JP2012512871A5 JP2011542220A JP2011542220A JP2012512871A5 JP 2012512871 A5 JP2012512871 A5 JP 2012512871A5 JP 2011542220 A JP2011542220 A JP 2011542220A JP 2011542220 A JP2011542220 A JP 2011542220A JP 2012512871 A5 JP2012512871 A5 JP 2012512871A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- dipyrido
- chloro
- pyrrol
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 derivatives Substances 0.000 claims 21
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- CCGWUONHYYBZHH-UHFFFAOYSA-N ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1=CC=CC=C1 Chemical compound ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1=CC=CC=C1 CCGWUONHYYBZHH-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- 230000001668 ameliorated effect Effects 0.000 claims 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005216 haloheteroaryl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- KJQMULVEACAHAA-UHFFFAOYSA-N 2-(4-chloro-2-pyridin-2-yl-1h-pyrrol-3-yl)pyridine Chemical compound ClC1=CNC(C=2N=CC=CC=2)=C1C1=CC=CC=N1 KJQMULVEACAHAA-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- RCKHVRMFUOLATQ-UHFFFAOYSA-N C1=C(F)C(C)=CC=C1NC1=CC=NC2=C1C(CNCC1)=C1N2 Chemical compound C1=C(F)C(C)=CC=C1NC1=CC=NC2=C1C(CNCC1)=C1N2 RCKHVRMFUOLATQ-UHFFFAOYSA-N 0.000 claims 1
- FZWQXCQAEPNRPY-UHFFFAOYSA-N C1=CC(Cl)=CC=C1S(=O)(=O)N1CC(C2=CC(Cl)=CN=C2N2)=C2CC1 Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1CC(C2=CC(Cl)=CN=C2N2)=C2CC1 FZWQXCQAEPNRPY-UHFFFAOYSA-N 0.000 claims 1
- DPFIEJRFQYZWEP-UHFFFAOYSA-N C1=CC(F)=CC=C1C(=O)N1CC(C2=C(NC=3C=CC=CC=3)C=CN=C2N2)=C2CC1 Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C2=C(NC=3C=CC=CC=3)C=CN=C2N2)=C2CC1 DPFIEJRFQYZWEP-UHFFFAOYSA-N 0.000 claims 1
- FOZKSELDKAYYBP-UHFFFAOYSA-N C1=CC(F)=CC=C1C1=CC=NC2=C1C(CNCC1)=C1N2 Chemical compound C1=CC(F)=CC=C1C1=CC=NC2=C1C(CNCC1)=C1N2 FOZKSELDKAYYBP-UHFFFAOYSA-N 0.000 claims 1
- AFFGUXXRWXNITD-UHFFFAOYSA-N C1=CC(F)=CC=C1NC1=CC=NC2=C1C(CNCC1)=C1N2 Chemical compound C1=CC(F)=CC=C1NC1=CC=NC2=C1C(CNCC1)=C1N2 AFFGUXXRWXNITD-UHFFFAOYSA-N 0.000 claims 1
- YNSFMCFEKKHDEO-UHFFFAOYSA-N C1=CC(OC)=CC=C1NC1=CC=NC2=C1C(CNCC1)=C1N2 Chemical compound C1=CC(OC)=CC=C1NC1=CC=NC2=C1C(CNCC1)=C1N2 YNSFMCFEKKHDEO-UHFFFAOYSA-N 0.000 claims 1
- LXIBUERWWHBIHT-UHFFFAOYSA-N C1=CC(OC)=CC=C1S(=O)(=O)N1CC(C2=CC(Cl)=CN=C2N2)=C2CC1 Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CC(C2=CC(Cl)=CN=C2N2)=C2CC1 LXIBUERWWHBIHT-UHFFFAOYSA-N 0.000 claims 1
- KHRHRHYBIZXLBL-UHFFFAOYSA-N C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=NC2=C1C(CN(CC1)C(C)=O)=C1N2 Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=NC2=C1C(CN(CC1)C(C)=O)=C1N2 KHRHRHYBIZXLBL-UHFFFAOYSA-N 0.000 claims 1
- QGKLIBZTYMONEX-UHFFFAOYSA-N C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=NC2=C1C(CNCC1)=C1N2 Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=NC2=C1C(CNCC1)=C1N2 QGKLIBZTYMONEX-UHFFFAOYSA-N 0.000 claims 1
- GLHWNTACRFJTNK-UHFFFAOYSA-N C1=CC=C2C(NC=3C=CN=C4NC=5CCN(CC=5C4=3)C(=O)C)=CC=CC2=C1 Chemical compound C1=CC=C2C(NC=3C=CN=C4NC=5CCN(CC=5C4=3)C(=O)C)=CC=CC2=C1 GLHWNTACRFJTNK-UHFFFAOYSA-N 0.000 claims 1
- ARVCXTIZULGFEV-UHFFFAOYSA-N C1=CC=CC2=CC(NC=3C=CN=C4NC=5CCN(CC=5C4=3)C(=O)C)=CC=C21 Chemical compound C1=CC=CC2=CC(NC=3C=CN=C4NC=5CCN(CC=5C4=3)C(=O)C)=CC=C21 ARVCXTIZULGFEV-UHFFFAOYSA-N 0.000 claims 1
- IHPMGPPBAZGPBD-UHFFFAOYSA-N C1C=2C3=CC(Cl)=CN=C3NC=2CCN1CC1=CC=CC(C#N)=C1 Chemical compound C1C=2C3=CC(Cl)=CN=C3NC=2CCN1CC1=CC=CC(C#N)=C1 IHPMGPPBAZGPBD-UHFFFAOYSA-N 0.000 claims 1
- DVAMISMDFXJHAK-UHFFFAOYSA-N C1C=2C3=CC(Cl)=CN=C3NC=2CCN1CCN1CCOCC1 Chemical compound C1C=2C3=CC(Cl)=CN=C3NC=2CCN1CCN1CCOCC1 DVAMISMDFXJHAK-UHFFFAOYSA-N 0.000 claims 1
- XLUFGPMHUDSUPZ-UHFFFAOYSA-N C1C=2C3=CC(Cl)=CN=C3NC=2CCN1S(=O)(=O)C1=CC=C(C#N)C=C1 Chemical compound C1C=2C3=CC(Cl)=CN=C3NC=2CCN1S(=O)(=O)C1=CC=C(C#N)C=C1 XLUFGPMHUDSUPZ-UHFFFAOYSA-N 0.000 claims 1
- BSAHINYSDJPNPW-UHFFFAOYSA-N C1C=2C3=CC(Cl)=CN=C3NC=2CCN1S(=O)(=O)C1=CC=CC(C#N)=C1 Chemical compound C1C=2C3=CC(Cl)=CN=C3NC=2CCN1S(=O)(=O)C1=CC=CC(C#N)=C1 BSAHINYSDJPNPW-UHFFFAOYSA-N 0.000 claims 1
- MBBIKEZBYSWBKK-UHFFFAOYSA-N C1CNCC2=C1NC1=C2C(NC2=CC=C3OCOC3=C2)=CC=N1 Chemical compound C1CNCC2=C1NC1=C2C(NC2=CC=C3OCOC3=C2)=CC=N1 MBBIKEZBYSWBKK-UHFFFAOYSA-N 0.000 claims 1
- HMQCDDXIAXULPU-UHFFFAOYSA-N C=12C=3CN(C(=O)C)CCC=3NC2=NC=CC=1NC1=CC=C(F)C=C1 Chemical compound C=12C=3CN(C(=O)C)CCC=3NC2=NC=CC=1NC1=CC=C(F)C=C1 HMQCDDXIAXULPU-UHFFFAOYSA-N 0.000 claims 1
- MOWRZSNHJMJUCD-UHFFFAOYSA-N C=12C=3CN(C(=O)C)CCC=3NC2=NC=CC=1NC1=CC=CC(F)=C1 Chemical compound C=12C=3CN(C(=O)C)CCC=3NC2=NC=CC=1NC1=CC=CC(F)=C1 MOWRZSNHJMJUCD-UHFFFAOYSA-N 0.000 claims 1
- PQESTNVMBBKJMU-UHFFFAOYSA-N C=12C=3CN(C(=O)C)CCC=3NC2=NC=CC=1NC1=CC=CC=C1 Chemical compound C=12C=3CN(C(=O)C)CCC=3NC2=NC=CC=1NC1=CC=CC=C1 PQESTNVMBBKJMU-UHFFFAOYSA-N 0.000 claims 1
- HVSDBJVRUGSNDU-UHFFFAOYSA-N C=12C=3CNCCC=3NC2=NC=CC=1NC1=CC=CC=C1 Chemical compound C=12C=3CNCCC=3NC2=NC=CC=1NC1=CC=CC=C1 HVSDBJVRUGSNDU-UHFFFAOYSA-N 0.000 claims 1
- HTDOPZPUOADKFP-UHFFFAOYSA-N C=1C=C(NC=2C=3C=4CNCCC=4NC=3N=CC=2)C=CC=1NC(=O)C1=CC=CC=C1 Chemical compound C=1C=C(NC=2C=3C=4CNCCC=4NC=3N=CC=2)C=CC=1NC(=O)C1=CC=CC=C1 HTDOPZPUOADKFP-UHFFFAOYSA-N 0.000 claims 1
- GFORXSNJIFPUOY-UHFFFAOYSA-N C=1C=NC=2NC=3CCNCC=3C=2C=1NCC1=CC=CC=C1 Chemical compound C=1C=NC=2NC=3CCNCC=3C=2C=1NCC1=CC=CC=C1 GFORXSNJIFPUOY-UHFFFAOYSA-N 0.000 claims 1
- FAJYOHQPLLAKBZ-UHFFFAOYSA-N COC1=CC=C(OC)C(S(=O)(=O)N2CC=3C4=CC(Cl)=CN=C4NC=3CC2)=C1 Chemical compound COC1=CC=C(OC)C(S(=O)(=O)N2CC=3C4=CC(Cl)=CN=C4NC=3CC2)=C1 FAJYOHQPLLAKBZ-UHFFFAOYSA-N 0.000 claims 1
- VLASXWUMRLHNRK-UHFFFAOYSA-N COC1=CC=CC(CN2CC=3C4=CC(Cl)=CN=C4NC=3CC2)=C1 Chemical compound COC1=CC=CC(CN2CC=3C4=CC(Cl)=CN=C4NC=3CC2)=C1 VLASXWUMRLHNRK-UHFFFAOYSA-N 0.000 claims 1
- NMADMPUJLAAIFL-UHFFFAOYSA-N COC1=CC=CC(NC=2C=C3C=4CN(CCC=4NC3=NC=2)C(=O)OC(C)(C)C)=C1 Chemical compound COC1=CC=CC(NC=2C=C3C=4CN(CCC=4NC3=NC=2)C(=O)OC(C)(C)C)=C1 NMADMPUJLAAIFL-UHFFFAOYSA-N 0.000 claims 1
- MPPNFBQEXBHABR-UHFFFAOYSA-N COC1=CC=CC(S(=O)(=O)N2CC=3C4=CC(Cl)=CN=C4NC=3CC2)=C1 Chemical compound COC1=CC=CC(S(=O)(=O)N2CC=3C4=CC(Cl)=CN=C4NC=3CC2)=C1 MPPNFBQEXBHABR-UHFFFAOYSA-N 0.000 claims 1
- PBLZXKUJSFOOSN-UHFFFAOYSA-N COC1=CC=CC=C1NC1=CN=C(NC2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 Chemical compound COC1=CC=CC=C1NC1=CN=C(NC2=C3CN(CC2)C(=O)OC(C)(C)C)C3=C1 PBLZXKUJSFOOSN-UHFFFAOYSA-N 0.000 claims 1
- ADTRUVXLDTZKBF-UHFFFAOYSA-N ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CC1 Chemical compound ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CC1 ADTRUVXLDTZKBF-UHFFFAOYSA-N 0.000 claims 1
- FEBAUCUPFLJYHE-UHFFFAOYSA-N ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CCC1 Chemical compound ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CCC1 FEBAUCUPFLJYHE-UHFFFAOYSA-N 0.000 claims 1
- RRCLCQYUZCAXHR-UHFFFAOYSA-N ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CCCC1 Chemical compound ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CCCC1 RRCLCQYUZCAXHR-UHFFFAOYSA-N 0.000 claims 1
- NURPTIXBGDGRND-UHFFFAOYSA-N ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CCCCC1 Chemical compound ClC1=CC=C2OCOC2=C1NC(C=1C=2C3)=CC=NC=1NC=2CCN3C(=O)C1CCCCC1 NURPTIXBGDGRND-UHFFFAOYSA-N 0.000 claims 1
- YYOISBSRWUUONQ-UHFFFAOYSA-N ClC1=CC=CC(C(=O)N2CC=3C4=C(NC=5C=CC(NC(=O)C=6C=CC=CC=6)=CC=5)C=CN=C4NC=3CC2)=C1 Chemical compound ClC1=CC=CC(C(=O)N2CC=3C4=C(NC=5C=CC(NC(=O)C=6C=CC=CC=6)=CC=5)C=CN=C4NC=3CC2)=C1 YYOISBSRWUUONQ-UHFFFAOYSA-N 0.000 claims 1
- KUDDHIYXAMFOKM-UHFFFAOYSA-N ClC1=CC=CC(C(=O)N2CC=3C4=C(NC=5C=CC=CC=5)C=CN=C4NC=3CC2)=C1 Chemical compound ClC1=CC=CC(C(=O)N2CC=3C4=C(NC=5C=CC=CC=5)C=CN=C4NC=3CC2)=C1 KUDDHIYXAMFOKM-UHFFFAOYSA-N 0.000 claims 1
- CGDAQQBGZQEHPI-UHFFFAOYSA-N ClC1=CC=CC(NC(=O)N2CC=3C4=C(NC=5C=CC=CC=5)C=CN=C4NC=3CC2)=C1 Chemical compound ClC1=CC=CC(NC(=O)N2CC=3C4=C(NC=5C=CC=CC=5)C=CN=C4NC=3CC2)=C1 CGDAQQBGZQEHPI-UHFFFAOYSA-N 0.000 claims 1
- QETLKPDSFDKEEJ-UHFFFAOYSA-N ClC1=CC=CC(S(=O)(=O)N2CC=3C4=C(NC=5C=CC=CC=5)C=CN=C4NC=3CC2)=C1 Chemical compound ClC1=CC=CC(S(=O)(=O)N2CC=3C4=C(NC=5C=CC=CC=5)C=CN=C4NC=3CC2)=C1 QETLKPDSFDKEEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- YVTOVGRROHPGQH-UHFFFAOYSA-N FC1=CC=CC(NC=2C=3C=4CNCCC=4NC=3N=CC=2)=C1 Chemical compound FC1=CC=CC(NC=2C=3C=4CNCCC=4NC=3N=CC=2)=C1 YVTOVGRROHPGQH-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- INVYSLWXPIEDIQ-UHFFFAOYSA-N cyclobutanecarbaldehyde Chemical group O=CC1CCC1 INVYSLWXPIEDIQ-UHFFFAOYSA-N 0.000 claims 1
- LIVQKHTVWSQZOY-UHFFFAOYSA-N cyclohexylmethanone Chemical group O=[C+]C1CCCCC1 LIVQKHTVWSQZOY-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical group O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 150000003335 secondary amines Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20302208P | 2008-12-18 | 2008-12-18 | |
| US61/203,022 | 2008-12-18 | ||
| PCT/US2009/066534 WO2010080253A1 (en) | 2008-12-18 | 2009-12-03 | Tricyclic azaindoles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015122169A Division JP6109880B2 (ja) | 2008-12-18 | 2015-06-17 | 三環式アザインドール |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012512871A JP2012512871A (ja) | 2012-06-07 |
| JP2012512871A5 true JP2012512871A5 (cg-RX-API-DMAC10.html) | 2013-01-31 |
Family
ID=41682740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542220A Pending JP2012512871A (ja) | 2008-12-18 | 2009-12-03 | 三環式アザインドール |
| JP2015122169A Expired - Fee Related JP6109880B2 (ja) | 2008-12-18 | 2015-06-17 | 三環式アザインドール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015122169A Expired - Fee Related JP6109880B2 (ja) | 2008-12-18 | 2015-06-17 | 三環式アザインドール |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8853391B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2367822B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2012512871A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2009336040B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2745085C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2603208T3 (cg-RX-API-DMAC10.html) |
| IL (1) | IL213589A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010080253A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2734552T3 (es) | 2010-04-16 | 2019-12-10 | Ac Immune Sa | Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide |
| BR112015021386A2 (pt) * | 2013-03-14 | 2017-07-18 | Bristol Myers Squibb Co | moduladores de ácido biciclo [2.2.2] gpr120 |
| GB201704325D0 (en) * | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
| CN111757882B (zh) | 2018-01-05 | 2023-08-22 | Ac免疫有限公司 | 用于治疗、减轻或预防与Tau聚集体相关的病症的化合物 |
| CN112313230B (zh) * | 2018-06-04 | 2024-03-15 | Ac免疫有限公司 | 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物 |
| EA202091395A1 (ru) * | 2018-06-04 | 2020-10-01 | Ас Иммьюн Са | ПРОИЗВОДНЫЕ 1,3,4,5-ТЕТРАГИДРО-2Н-ПИРИДО[4,3-b]ИНДОЛА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ, ТАКИХ КАК БОЛЕЗНЬ АЛЬЦГЕЙМЕРА |
| EP3836919A4 (en) | 2018-08-16 | 2022-05-18 | Recreo Pharmaceuticals Inc. | 1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indole derivative compounds and uses thereof |
| CA3131805C (en) | 2019-03-01 | 2023-11-21 | Ac Immune Sa | Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268771A (en) * | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | Azacarbazoles |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US6589954B1 (en) * | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| US20040014676A1 (en) * | 2001-07-09 | 2004-01-22 | Ramalinga Dharanipragada | SRC kinase inhibitors useful for treating osteoporosis |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2010500961A (ja) * | 2006-08-02 | 2010-01-14 | 武田薬品工業株式会社 | α−カルボリン誘導体およびその製造方法 |
| CN101687864A (zh) * | 2007-06-26 | 2010-03-31 | 阿斯利康(瑞典)有限公司 | 作为组织蛋白酶k抑制剂的1-氰基环丙基-衍生物 |
| RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
-
2009
- 2009-12-03 US US13/140,357 patent/US8853391B2/en not_active Expired - Fee Related
- 2009-12-03 AU AU2009336040A patent/AU2009336040B2/en not_active Ceased
- 2009-12-03 ES ES09793373.3T patent/ES2603208T3/es active Active
- 2009-12-03 JP JP2011542220A patent/JP2012512871A/ja active Pending
- 2009-12-03 CA CA2745085A patent/CA2745085C/en not_active Expired - Fee Related
- 2009-12-03 EP EP09793373.3A patent/EP2367822B1/en not_active Not-in-force
- 2009-12-03 WO PCT/US2009/066534 patent/WO2010080253A1/en not_active Ceased
-
2011
- 2011-06-16 IL IL213589A patent/IL213589A/en active IP Right Grant
-
2015
- 2015-06-17 JP JP2015122169A patent/JP6109880B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10525037B2 (en) | Compounds for treatment of cancer | |
| CN107108637B (zh) | 三唑并嘧啶化合物及其用途 | |
| US9382232B2 (en) | Quinoline and cinnoline derivatives and their applications | |
| KR20260047565A (ko) | 통증에 대한 신규 치료 | |
| US20210070712A1 (en) | Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy | |
| AU2017200232A1 (en) | Combination therapy | |
| KR20170069199A (ko) | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 | |
| KR20140107574A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| AU2018237047A2 (en) | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain | |
| JP2010516692A (ja) | 化学療法剤に対し抵抗性を有する癌の処置 | |
| TW201249805A (en) | Use of sigma ligands in bone cancer pain | |
| BRPI0710293A2 (pt) | n-(aril- ou heteroaril)-pirazol[1,5-a]pirimidinas 3-substituìdas como inibidores de cinase | |
| AU2016252860B2 (en) | Compositions and methods for inhibiting kinases | |
| KR20140107573A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| WO2014067417A1 (zh) | 新的喹啉类化合物及其用途 | |
| KR20140104047A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| CN106029099A (zh) | 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合 | |
| CN119255992A (zh) | 杂环衍生物及其组合物和应用 | |
| CN119325468A (zh) | 杂环衍生物及其组合物和应用 | |
| JP2012512871A (ja) | 三環式アザインドール | |
| KR20150067323A (ko) | 조합물 | |
| CN112237579B (zh) | 药物组合及其用途 | |
| KR101929725B1 (ko) | 의학적 적용을 위한 3-(1,2,4-트리아졸로[4,3-a]피리딘-3-일에티닐)-4-메틸-N-(4-((4-메틸피페라진-1-일)메틸)-3-트리플루오로메틸페닐)벤즈아미드의 신규 결정질 염 형태 | |
| KR20150001967A (ko) | 티에노[3,2-ｄ]피리미딘 유도체의 Ｔ315Ｉ-Ｂｃｒ-Ａｂｌ 점돌연변이종의 저해 활성 | |
| CN102007139A (zh) | 用于治疗疼痛的贝洛塞平、its对映体及其类似物 |